ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA
January 11, 2022CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors... -
CAR T-Cell Immunotherapy Rids Woman of Tough-to-Treat Lupus
August 06, 2021In a first, researchers have used genetically tweaked immune system cells to send a woman's severe lupus into remission. -
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy
August 03, 2021Fate Therapeutics , inc. announced today that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies.
Pharma Sources Insight January 2025
